Abstract
Introduction

Worldwide, 170 million people are infected with hepatitis C virus (HCV) and more than 350 million people by the hepatitis B virus
. Routine screening for HBV and HCV using second-or third-generation enzyme linked immunosorbent assay (ELISA) assays or novel sol-gel-based antigen microarray systems allow the sensitive detection of respective viral hepatitis antigens or antibodies with high diagnostic accuracy, sensitivity and specificity [3] . Nevertheless [4] [5] [6] [7] [8] . Therefore [9, 10] , non-alcoholic fatty liver disease [11] , HCV-induced fibrogenesis [12, 13] and other. One HCV-based study was also performed with the SELDI approach with HCC and fibrosis patient sera to distinguish between low stage fibrosis versus cirrhosis and HCC [14] . [15] . However, these proteins are highly abundant and their overall disease specificity is questionable. In fact, only 1% of the entire protein content of serum is made up of proteins that are considered to be in low abundance and of great interest in proteomic studies in search of potential biomarkers [16] .
In a recent report using a traditional and very time consuming 2D-polyacrylamide gel electrophoresis/LC-MS/MS platform, seven individual protein spots were identified as either significantly increased (␣2-macroglobulin, haptoglobin, an albumin fragment) or decreased (complement C-4, serum retinol binding protein, apolipoprotein A-I, and two isoforms of apolipoprotein A-IV) in serum of HCV patients with advanced fibrosis
A more recent proteomic-based study has identified a fragment of the complement component C3a as a potential marker for the early detection of HCV-related liver insults [17] . The 
Materials and methods
Serum samples
The serum samples of HCV-infected patients (n = 179) used in this study were obtained from the central serum-/DNA-bank of the Hep-Net without any further selection [19] . Control samples (n = 195) were drawn from healthy individuals under strict routine protocols as outlined elsewhere [20] . All 
MS/MS sequence analysis
MALDI MS/MS measurements of selected proteins were performed with an Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics
Results
General aspects and study population
methods'). Representative biopsies stained by Gomori (A-D) or by hemalaun and eosin (E-G) were graded (G) and staged (S) to: (A) G2/S1, (B) G2/S2, (C) G2/S3, (D) G2/S4, (E) G1/S1, (F) G2/S2, and (G) G3/S3, respectively. Magnification: (A)-(C) and (E)-(G): 100ϫ; (D): 40ϫ.
To contemplate the results generated by applying the GA, selected peaks were used to assemble the GA-based model and peak associated ROC curves are presented in Figure 3 . Fig. 3 ) that were decreased in serum drawn from HCV-infected patients were identified both with high probability as fragments of kininogen 1 (Fig. 4) . Details are shown in needle biopsy is doubtful and intra-and interoperator reproducibility of pathological classifications is potentially prone to error [5, 6] [28, 29] . This development has culminated in screening and profiling of complex biomarker patterns in clinical proteomics to detect a molecular fingerprint that is specific for one disease. In hepatology, proteomic profiling were already successful in the assessment of cholangiocarcinoma [30] , HCC [9, 31, 32] , and nonalcoholic fatty liver disease [11] . In an exploratory study using serum samples from HCV-infected patients in a SELDI-TOF-MS approach, the authors used an elaborating pre-fractionation process following additional cationic pre-fractionation [13] . In comparison to our results the authors focused on differences in disease progression without comparison to healthy controls whereas our focus was defined as discovery of a potential clinical tool to detect fibrosis of all stages with high sensitivity and specificity. A recent publication based on 2D gel electrophoresis showed novel but high abundant proteins that were associated with fibrosis progression in HCV patients [15] (Fig. 5A ) and, moreover, significant (P ϭ 0.0227) lowered in patients with strong intrahepatic inflammation (staged Ͼ2 in liver biopsy) (Fig. 5G) . Immunocytochemical staining further revealed that non parenchymal liver cells, most likely Kupffer cells, are the major source of thymosin-␤4 in liver (Fig. 6 ). This result is in agreement with two recent reports demonstrating that expression of thymosin-␤4 is found in activated Kupffer cells [26, 39] . However, it is known that thymosin-␤4 is expressed in many organs and tissues [26] (Fig. 5G) .
Identification of selected peptides/proteins
Identification of three peptides/ proteins utilized in the GA-based model was successful via MS/MS. Analysis of the 2080 and 2209 Da peptides (peaks 1 and 2 in
Quantitative real-time PCR data from human liver biopsies
We next addressed the question if the observed elevated expression of thymosin-␤4 and decreased expression of kininogen-1 in patients suffering liver disease was found at mRNA expression in respective liver biopsies. Moreover, we addressed the question if hepatic expression of thymosin-␤4 and kininogen-1 is influenced by the aetiology that is causative for liver disease. To do so, we isolated mRNA from livers of an independent cohort that contained 42 patients (11 alcoholics, 11 PSC, 12 HCV, 8 HBV) and five healthy controls and performed qRT-PCR for thymosin-␤4 and kininogen-1 (Fig. 5). This analysis revealed that the suppression of kininogen-1 was significant in patients with
In regard to kininogen-1 we confirmed previous findings [27] 
